Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-634-0 | CAS number: 123-54-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- repeated dose toxicity: dermal
- Remarks:
- other: 9 days
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1994-02-22 to 1995-04-06
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Conduction and documentation of study acceptable. Study report available.
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 995
- Report date:
- 1995
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 001
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: stated in report
- Deviations:
- no
- Principles of method if other than guideline:
- New Zealand White rabbits were treated by 6 h occluded cutaneous application with undiluted 2,4-pentanedione at dose volumes of 0.25, 1.0 and 1.5 ml/kg body weight. Animals in the control group received occluded applications of Milli-Q filtered water at a volume of 1.5 ml/kg bw. The test or control substance was applied to the clipped dorsal surface of the rabbits. Twelve animals/sex/group were used for the control and high dose groups, 6 animals/sex/group for mid and low dose groups. The original study de-sign included dosing for 5 days the first week and 4 day the second week. The addi-tional 6 animals/sex/group in the controls and the high dose group were used for a 4 week recovery period. Due to mortality and signs of toxicity observable in mid and high dose groups, dosing was discontinued for these groups after day 4. Three surviving males and 2 surviving females from the 1463 mg/kg group were euthanized on day 4 while an additional 4 males and 3 females were retained without further dosing to day 12. Rabbits in the low dose group continued to receive a total of 9 doses (5 in the first week, 4 in the second). On day 12, 6 rabbits/sex from the control group were removed from the study since they were not required for their intended purpose as a recovery group. All other surviving rabbits were euthanized on day 12. Only 3 rabbits/sex from the control group were subjected to necropsy and histopathology. Monitors for toxicity included observations for clinical signs, including skin irritation, food consumption, water consumption, body weight and body weight change, organ weights, gross pathology and histopathology.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Pentane-2,4-dione
- EC Number:
- 204-634-0
- EC Name:
- Pentane-2,4-dione
- Cas Number:
- 123-54-6
- Molecular formula:
- C5H8O2
- IUPAC Name:
- pentane-2,4-dione
- Details on test material:
- - Name of test material (as cited in study report): 2,4-Pentanedione
- Physical state: liquid
- Stability under test conditions: stable
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: HPR Inc denver, PA, USA
- Age at study initiation: 15 to 18 days
- Weight at study initiation: 2.5 to 3 kg
- Fasting period before study: not reported
- Housing: individually
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 61 - 70 °F
- Humidity (%): 40 - 60 %
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Area of exposure: 4 x 4 inch
- Type of wrap if used: lycra/spandex jacket
- Time intervals for shavings or clipplings: clipping
REMOVAL OF TEST SUBSTANCE
- Washing (if done): not applicable
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 0.25, 1.0, 1.5 ml/kg
USE OF RESTRAINERS FOR PREVENTING INGESTION: yes - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- not applicable, since substance was administered in neat
- Duration of treatment / exposure:
- 9 days
- Frequency of treatment:
- 5 days first week, 4 days second week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.25, 1.0, 1.5 ml/kg
Basis:
nominal per unit body weight
- No. of animals per sex per dose:
- 6 (mid and low dose group), 12 (high dose and control group)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Post-exposure period: 4 week recovery period
- Dose selection rationale: pretests
- Rationale for animal assignment (if not random): random
- Post-exposure recovery period in satellite groups: 4 weeks (half of control group) - Positive control:
- not applicable
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twiche daily
- Cage side observations checked in table were included.
DETAILED CLINICAL OBSERVATIONS: Yes
DERMAL IRRITATION (if dermal study): Yes / No / No data
BODY WEIGHT: Yes
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Day 4 and Day 12
- Anaesthetic used for blood collection: Yes (identity) / No / No data
- Animals fasted: No
- How many animals: all remaining animals in high dose and control group
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Day 4 and Day 12
- Animals fasted: No
- How many animals: all remaining animals in high dose and control group
URINALYSIS: Yes
- Time schedule for collection of urine: Day 4 and Day 12
- Metabolism cages used for collection of urine: No
- Animals fasted: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Other examinations:
- none
- Statistics:
- Results of quantitative continuous variables (such as body weight changes) were intercompared among the treatment groups and one control group by use of analysis of variance (ANOVA)and t-tests. The t-test were used when F value from the ANOVA was significant. When Levene's test indicated similar variances, and the ANOVA was significant, a pooled t-test was used for pairwise comparisons. When Levene's test indicated heterogeneous variances, all groups were compared by a ANOVA for unequal variances followed, when necessary, by a separate
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Dermal irritation:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Occluded cutaneous dosing of rabbits with 2,4-pentanedione for 3 or 4 days resulted in death of 5/12 males and 7/12 females in the 1.5 ml/kg (1463 mg/kg) group and 1/6 males and 3/6 females in the 1.0 ml/kg (975 mg/kg) group. Skin irritation was observed in all dose groups. Time to onset and severity of skin irritation were generally dose-dependent and persistent in all dose groups. Signs of skin irritation included erythema, edema, desquamation/exfoliation, excoriation, fissuring, necrosis and/or ecchymosis. In the mid and high dose groups of rabbits during the first few days of the study, several signs of systemic toxicity were evident. Numerous animals from these dose groups were hypoactive, uncoordinated and/or prostrate, had tremors, salivation, gasping and/or convulsions, and some had blue cutis of the nasal area suggestive of cyanosis. Furthermore, these groups lost mean body weight and had decreased food con-sumption during the first few days of the study. After cessation of dosing in these dose groups, mean food consumption generally returned to control values while mean body weight gains were increased over control values. Excessive vocalization, slow or la-boured breathing, and/or red perioral discharge were also observed in some high dose group animals until cessation of dosing. In the low dose group there were no mortalities, clinical signs of systemic toxicity, or effects on body weight or food consumption. Gross and microscopic evaluation at both day 4 and 12 confirmed dose-related skin irritation in all treatment groups. Microscopic lesions included acanthosis, subcutaneous edema, dermatitis, hemorrhage, congestion and/or necrosis. There were also numerous rabbits with hemorrhaging in various sections of the brain, including the meninges. Additionally, a number of brain sections showed neuronal degeneration, including the hypothalamus, mid brain, piriform cortex, pons and/or hippocampus. At both day 4 and 12, the thymus or thymic region, spleen, and/or lymph nodes of several animals of both sexes from the mid and high dose groups were congested and/or hemorrhaged; some animals also had lymphoid depletion or necrosis. This observation, combined with decreased lymphocyte and eosinophil counts in the high dose group at day 4, suggested possible effects on the immune system. Since the animals from the mid and high dose group had severe skin irritation and many signs of systemic effects a definitive conclusion regarding a treatment related response to the immune system is not possible, as discussed by the study authors. Except clinical pathology changes that may have been related to the skin irritation, no substance related differences from controls were reported in the low dose group. According to the systemic effects observed, 244 mg/kg bw and 975 mg/kg bw correspond to the NOAEL and LOAEL of this dermal study, respectively.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 244 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: overall effects
- Dose descriptor:
- LOAEL
- Effect level:
- 975 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: body weight; haematology; clinical chemistry; histopathology;
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Under the conditions used the systemic NOAEL of the substance is 244 mg/Kg bw/d.
- Executive summary:
New Zealand White rabbits were treated by 6 h occluded cutaneous application with undiluted 2,4-pentanedione at dose volumes of 0.25, 1.0 and 1.5 ml/kg body weight for 9 days. Animals in the control group received occluded applications of Milli-Q filtered water at a volume of 1.5 ml/kg bw. The test or control substance was applied to the clipped dorsal surface of the rabbits. Twelve animals/sex/group were used for the control and high dose groups, 6 animals/sex/group for mid and low dose groups. The original study design included dosing for 5 days the first week and 4 day the second week. The additional 6 animals/sex/group in the controls and the high dose group were used for a 4 week recovery period. Due to mortality and signs of toxicity observable in mid and high dose groups, dosing was discontinued for these groups after day 4. Three surviving males and 2 surviving females from the 1463 mg/kg group were euthanized on day 4 while an additional 4 males and 3 females were retained without further dosing to day 12. Rabbits in the low dose group continued to receive a total of 9 doses (5 in the first week, 4 in the second). On day 12, 6 rabbits/sex from the control group were removed from the study since they were not required for their intended purpose as a recovery group. All other surviving rabbits were euthanized on day 12. 3 rabbits/sex from the control group were subjected to necropsy and histopathology. Monitors for toxicity included observations for clinical signs, including skin irritation, food consumption, water consumption, body weight and body weight change, organ weights, gross pathology and histopathology. Used doses of 0.25, 1.0 and 1.5 ml/kg bw as given by the authors equivalent to 244, 975 and 1463 mg/kg bw, respectively.
Occluded cutaneous dosing of rabbits with 2,4-pentanedione for 3 or 4 days resulted in death of 5/12 males and 7/12 females in the 1.5 ml/kg (1463 mg/kg) group and 1/6 males and 3/6 females in the 1.0 ml/kg (975 mg/kg) group. Skin irritation was observed in all dose groups. Time to onset and severity of skin irritation were generally dose-dependent and persistent in all dose groups. Signs of skin irritation included erythema, edema, desquamation/exfoliation, excoriation, fissuring, necrosis and/or ecchymosis. In the mid and high dose groups of rabbits during the first few days of the study, several signs of systemic toxicity were evident. Numerous animals from these dose groups were hypoactive, uncoordinated and/or prostrate, had tremors, salivation, gasping and/or convulsions, and some had blue cutis of the nasal area suggestive of cyanosis. Furthermore, these groups lost mean body weight and had decreased food consumption during the first few days of the study. After cessation of dosing in these dose groups, mean food consumption generally returned to control values while mean body weight gains were increased over control values. Excessive vocalization, slow or laboured breathing, and/or red perioral discharge were also observed in some high dose group animals until cessation of dosing. In the low dose group there were no mortalities, clinical signs of systemic toxicity, or effects on body weight or food consumption. Gross and microscopic evaluation at both day 4 and 12 confirmed dose-related skin irritation in all treatment groups. Microscopic lesions included acanthosis, subcutaneous edema, dermatitis, hemorrhage, congestion and/or necrosis. There were also numerous rabbits with hemorrhaging in various sections of the brain, including the meninges. Additionally, a number of brain sections showed neuronal degeneration, including the hypothalamus, mid brain, piriform cortex, pons and/or hippocampus. At both day 4 and 12, the thymus or thymic region, spleen, and/or lymph nodes of several animals of both sexes from the mid and high dose groups were congested and/or hemorrhaged; some animals also had lymphoid depletion or necrosis. This observation, combined with decreased lymphocyte and eosinophil counts in the high dose group at day 4, suggested possible effects on the immune system. Since the animals from the mid and high dose group had severe skin irritation and many signs of systemic effects a definitive conclusion regarding a treatment related response to the immune system is not possible, as discussed by the study authors. Except clinical pathology changes that may have been related to the skin irritation, no substance related differences from controls were reported in the low dose group. According to the systemic effects observed, 244 mg/kg bw and 975 mg/kg bw correspond to the NOAEL and LOAEL of this dermal study, respectively.
The severity of the skin irritation, as well as systemic toxicity, observed in the study was considered to be at least partially related to the occlusive conditions used in this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
